Access_Logo_RGB_Full_Color2020.jpg
Triyam Recognized on Inc. 5000 List for the Fourth Consecutive Year
August 15, 2024 09:00 ET | Access Information Management Shared Services, LLC
Company ranking leveled up 999 spots on this highlighted list of America’s Fastest-Growing Private Companies
MustangBioLogo.jpg
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 21, 2024 16:01 ET | Mustang Bio, Inc.
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
MustangBioLogo.jpg
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 20, 2024 08:00 ET | Mustang Bio, Inc.
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
AvePoint-400x400.jpg
AvePoint Named to Inc.’s Annual List of Best Workplaces for 2024
June 18, 2024 08:45 ET | AvePoint, Inc.
JERSEY CITY, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the global leader in robust data management and data governance, today announced it has been named to Inc.’s annual Best...
MustangBioLogo.jpg
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
June 17, 2024 08:30 ET | Mustang Bio, Inc.
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and...
MustangBioLogo.jpg
Mustang Bio Announces Pricing of $4 Million Public Offering
April 29, 2024 20:00 ET | Mustang Bio, Inc.
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Inc_FF100_SocialToolkit_2024_1200x675
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
April 09, 2024 09:15 ET | Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
MustangBioLogo.jpg
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
March 28, 2024 09:00 ET | Mustang Bio, Inc.
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth...
MustangBioLogo.jpg
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 11, 2024 16:05 ET | Mustang Bio, Inc.
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
MustangBioLogo.jpg
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 07, 2024 07:30 ET | Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...